Translational Scientist / Sr Scientist – Cancer Immunotherapy Biomarker Lead
NGM Biopharmaceuticals, Inc. is a biopharmaceutical company dedicated to discovering and developing the next generation of medicines for the treatment of serious diseases. Our experienced scientific team has joined forces with an impressive group of industry professionals, Nobel Laureates and other distinguished researchers to build a company where innovation and cutting-edge science has provided the foundation for a robust drug discovery engine that has a track record of generating one new IND candidate per year. NGM’s current pipeline of clinical-stage programs consists of five drug candidates targeting liver and metabolic diseases, retinal diseases and cancer. The most advanced drug candidate, aldafermin (NGM282), is in Phase 2b clinical studies in non-alcoholic steatohepatitis (NASH) and is wholly-owned by NGM. Another drug candidate, NGM621, is in a Phase 2 study in geographic atrophy (GA) secondary to age-related macular degeneration (AMD). NGM’s strategic collaboration with Merck, with a current term running to March 2022, provides us with the resources and flexibility to pursue our ambitious R&D goals and further extend our pipeline of novel drug candidates.
We are seeking a highly motivated PhD-level scientist to lead biomarker development for cancer immunotherapy within our Translational Science department. The successful candidate will have an in-depth understanding of biomarker development for cancer immunotherapy and apply this knowledge to advance the development of novel therapeutics. Working closely with the discovery research team, the candidate will develop pharmacodynamic and predictive biomarker plans, addressing the mechanism(s) of action required for anti-tumor efficacy. In addition to fulfilling these requirements as an independent contributor, the candidate will establish and manage external collaborations and contract research organization partners (CROs). Leveraging clinical samples from ongoing studies, the candidate will develop and execute a research plan to address innate and adaptive resistance mechanisms, and reverse translation efforts. The successful candidate will serve as the translational science lead on project teams and will be accountable for biomarker strategies and timelines.
- Expertise in multi-parameter flow cytometry
- Proficiency in tissue culture and primary immune cell assays
- Prior experience in myeloid cell biology or biomarkers for cancer immunotherapy preferred
- Established strong publication record in biomedical science
- Strong interpersonal, organization, time-management, and verbal and written communication skills
- PhD in immunology, or relevant scientific field in biomedical sciences with extensive experience in immunology
- Post-doctoral experience in immunology is preferred
- In-depth knowledge of the fundamentals of immunology and tumor biology
- Knowledge of biomarker discovery and development, including assay development and validation, tissue and soluble biomarker platforms
NGM offers a creative, collaborative, highly challenging scientific environment, along with a strong compensation package that includes salary, stock options, 401(k) and a comprehensive benefits package.
Interested applicants should click apply
We have become aware of false offers of employment being made by individuals impersonating NGM representatives in order to collect personal information and/or payment. Please exercise caution when receiving unsolicited recruiting offers. NGM always lists all open positions on the NGM careers page and all employment applications must be submitted through our online portal. NGM will never solicit payment or payment information from candidates. Please be advised that NGM is not currently hiring in any countries other than the US. We never request that candidate information be sent to a non-ngmbio.com email address.
Note to Recruitment Agencies: Please do not forward any agency résumés. NGM Bio is not responsible for any fees related to résumés that are unsolicited.